Chicago, IL24 Active Studies

Erectile Dysfunction Clinical Trials in Chicago, IL

Find 24 actively recruiting erectile dysfunction clinical trials in Chicago, IL. Connect with local research sites and explore new treatment options.

24
Active Trials
22
Sponsors
27,086
Enrolling

Recruiting Erectile Dysfunction Studies in Chicago

RecruitingChicago, ILNCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

20,000 participants
UMC Utrecht
View Study Details
RecruitingChicago, ILNCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors ...

933 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingChicago, ILNCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingChicago, ILNCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

740 participants
Daiichi Sankyo
View Study Details
RecruitingChicago, ILNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingChicago, ILNCT05417594

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

695 participants
AstraZeneca
View Study Details
RecruitingChicago, ILNCT06380751

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...

500 participants
AstraZeneca
View Study Details
RecruitingChicago, ILNCT06311214

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

500 participants
National Cancer Institute (NCI)
View Study Details
RecruitingChicago, ILNCT05315700

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

350 participants
ORIC Pharmaceuticals
View Study Details
RecruitingChicago, ILNCT05443126

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)...

265 participants
Ellipses Pharma
View Study Details
RecruitingChicago, ILNCT06635785

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....

204 participants
OncoC4, Inc.
View Study Details
RecruitingChicago, ILNCT05512754

Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen

The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA....

200 participants
University of Chicago
View Study Details
RecruitingChicago, ILNCT03937154

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer o...

162 participants
Amgen
View Study Details
RecruitingChicago, ILNCT06603844

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

156 participants
Corbus Pharmaceuticals Inc.
View Study Details
RecruitingChicago, ILNCT06413680

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

150 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingChicago, ILNCT06055439

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

135 participants
Chimeric Therapeutics
View Study Details
RecruitingChicago, ILNCT06898450

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main qu...

134 participants
Nimbus Wadjet, Inc.
View Study Details
RecruitingChicago, ILNCT05394103

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

130 participants
Qurient Co., Ltd.
View Study Details
RecruitingChicago, ILNCT06049680

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipi...

100 participants
Fresenius Kabi
View Study Details
RecruitingChicago, ILNCT05639543

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH)....

80 participants
Intercept Pharmaceuticals
View Study Details
RecruitingChicago, ILNCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingChicago, ILNCT05705024

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of...

38 participants
University of Illinois at Chicago
View Study Details
RecruitingChicago, ILNCT06712875

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, ...

27 participants
Ann & Robert H Lurie Children's Hospital of Chicago
View Study Details
RecruitingChicago, ILNCT04796012

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/r...

23 participants
University of Texas Southwestern Medical Center
View Study Details

About Erectile Dysfunction Clinical Trials in Chicago

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 24 erectile dysfunction clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 27,086 participants. Research is being sponsored by UMC Utrecht, Regeneron Pharmaceuticals, Eli Lilly and Company and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Chicago — FAQ

Are there erectile dysfunction clinical trials in Chicago?

Yes, there are 24 erectile dysfunction clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 24 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated March 2, 2026 from ClinicalTrials.gov